Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

osive growth of clinical research in India. Mr. Maki's presentation is scheduled for 4:25 p.m.

About Cancer Cachexia and VT-122

Cancer cachexia results in severe wasting of muscle and connective tissue and is one of the most common debilitating and distressing conditions of advanced cancer. Severe cachexia is associated with extreme weakness, intolerance to chemotherapy and substantially reduced life expectancy. There is currently no FDA-approved therapy for cancer cachexia.

VT-122 targets inflammatory and other key pathways thought to be responsible for the onset and observed clinical symptoms of cancer cachexia. The use of VT-122 is currently being evaluated under a U.S. IND in a Phase 2 study being conducted concurrently at multiple sites in the U.S. and India. Results from the ongoing trial are expected by end of 2007.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' strategy involves combining individual generic drugs that have previously received regulatory approval for other indications and thus have established post-marketing safety records. Vicus leverages its proprietary science to design and patent novel drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue. Vicus' development programs are powered by its network of leading clinical investigators and partners in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical devel
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced an update on corporate and ... structure, commitment for future funding, ongoing clinical ... In corporate news, Chief Executive Officer ...
(Date:9/2/2014)... , Sept. 2, 2014  MEI Pharma, Inc. ... focused on the clinical development of novel therapies ... enrollment in a randomized Phase II clinical trial ... combination with azacitidine in patients with previously untreated ... placebo-controlled, double-blind study enrolled a total of 108 ...
(Date:9/2/2014)... Sept. 2, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... three drugs in its lipid franchise were highlighted in ... (ESC) Congress in Barcelona Spain . ... designed to provide effective and safe therapeutic options to ... of one commercialized drug and several other drugs in ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 2Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 3Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 5
... ... Dysmenorrhea Pain Medication, HOBOKEN, N.J., June 18 A ... periods,affecting millions of women each year, can be reduced naturally ... maritime,pine tree. The multi- center field study, published in the ...
... the Need for Testosterone Screening in At-Risk ... ... from a 12-month,international, multi-center study showed that treatment for low,testosterone with ... and sexual function among,hypogonadal men with Type 2 diabetes and/or Metabolic ...
Cached Medicine Technology:New Study: Pine Bark Significantly Reduces Menstrual Pain 2New Study: Pine Bark Significantly Reduces Menstrual Pain 3Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome 2Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome 3
(Date:9/2/2014)... News) -- The quality of Americans, diets has improved ... the rich and poor is growing, a new study ... to date that the extensive efforts by many groups ... some payoff, but it also indicates that these efforts ... doctoral student in the department of nutrition at the ...
(Date:9/2/2014)... Amy Norton HealthDay Reporter , ... want to lose weight and boost their heart health, cutting ... a new study suggests. In a small clinical trial ... a low-carbohydrate diet lost more weight over a year than ... bigger improvements in their cholesterol and triglyceride levels, the research ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... Magee Rehabilitation Hospital returns on September 19 at The ... Hill, Pennsylvania. Over the past 25 years, the Classic, ... more than $12 million for programs and services designed ... at Magee Rehabilitation Hospital. , “The Segal Classic ...
(Date:9/2/2014)... 02, 2014 North America Resectoscopes ... Market Outlook to 2020? provides key market data ... provides value, in millions of US dollars, volume ... within market segments –,     Rigid ... Reusable) Electrodes and Bipolar (Disposable and Reusable) Electrodes). ...
(Date:9/2/2014)... 02, 2014 Humility of Mary Health Partners ... at St. Elizabeth Health Center, 1044 Belmont Ave. , The ... more than 200 common health problems as well as tips ... injury, and advice on when to seek medical attention. ... in the Youngstown Room; the evening session runs from 5:30 ...
Breaking Medicine News(10 mins):Health News:Quality of U.S. Diet Improves, Slightly 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:HMHP Offers ‘Health at Home’ Workshop 2
... health problems outside the lungs, researchers say , , WEDNESDAY, ... and long-term toxic effects on the heart and blood ... cause death, a new report says. , The ... issue of the Journal of the American College ...
... Physician Accuracy And ... Reduces Radiation Exposure for Patients, AUSTIN, Texas, Aug. ... Institute (TCAI) at St. David,s Medical Center became,the first ... -- an enhancement to the state-of-the art Hansen Robotic ...
... ("Assurant"),(NYSE: AIZ ), a premier provider of ... that Jane Meyer,has been appointed senior vice president, ... vice president, organizational development and,corporate communications effective immediately. ... and Mr. Walker will continue to report to ...
... Daily Dietary Supplements to Introduce Fashion Week ... Survival Kit at Verrier Runway Show, ... its,first-ever fashion partnership with breakout designer Ashleigh Verrier to,promote "Style ... healthy beauty during one of the most exciting and fast-paced,fashion ...
... the National Institutes of Health (NIH) have found a mechanism ... the development of autoimmune disease when turned off. The findings ... of autoimmunity and could also have implications for the development ... as cancer and HIV. The study paper appears online today ...
... strength, agility tied to brain damage, even in the ... -- Physical frailty among the elderly may be linked ... patients develop dementia, new research reveals. , The finding, ... the notion that motor impairment in the elderly is ...
Cached Medicine News:Health News:Air Pollution Can Damage Heart, Blood Vessels, Too 2Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures 2Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures 3Health News:Assurant Announces Two Executive Appointments 2Health News:VIACTIV(R) Partners With Rising Fashion Label Verrier to Launch 'Style and Strength for Life' Health Initiative at Fall Fashion Week 2008 2Health News:VIACTIV(R) Partners With Rising Fashion Label Verrier to Launch 'Style and Strength for Life' Health Initiative at Fall Fashion Week 2008 3Health News:NIH scientists find a novel mechanism that controls the development of autoimmunity 2Health News:Physical Frailty Could Predict Alzheimer's Disease 2Health News:Physical Frailty Could Predict Alzheimer's Disease 3
... diagnostic capabilities combined with ease of use ... in its class. Ideal for office or ... system for Uroflowmetry, cystometry, leak point pressure, ... are available which make the OM-5 flexible ...
The Duet EnCompass Pelvic Floor Diagnostic System is the only equipment specifically designed to perform urodynamics, anorectal manometry, EMG and pudendal nerve latency studies on a single software ...
... The Corkscrew FT II (fully threaded) is ... designed to be inserted flush with the ... and anchor stability. The full thread design ... anchors with protruding eyelets. Especially advantageous when ...
... Corkscrew Parachute Tissue Anchor allows one step fixation ... ideal for arthroscopic knotless rotator cuff repair in ... has an outside thread diameter of 5 mm ... #2 FiberWire suspension sutures securely hold a thin, ...
Medicine Products: